VSAR Versartis, Inc.

19.80
0  -1%
Previous Close 19.90
Open 19.90
Price To book 4.59
Market Cap 693.91M
Shares 35,046,000
Volume 95,136
Short Ratio 2.63
Av. Daily Volume 292,560

SEC filingsSee all SEC filings

  1. 8-K - Current report 17789275
  2. DEF 14A - Other definitive proxy statements 17781656
  3. PRE 14A - Other preliminary proxy statements 17761362
  4. CT ORDER - Confidential treatment order 17751807
  5. 8-K - Current report 17732935

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due September 2017.
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
Phase 3 trial to be initiated 2H 2017.
VRS-317 VITAL
Growth hormone deficiency, or GHD - adult

Latest News

  1. Versartis reports 1Q loss
  2. Versartis Reports First Quarter 2017 Financial Results
  3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Versartis Inc. - VSAR
  4. Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations
  5. Versartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD
  6. Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
  7. Versartis to Host Conference Call to Review Data from ENDO 2017 on Long-Acting Somavaratan for Growth Hormone Deficiency
  8. Rennova Health and Versartis Have Different Reasons for Optimism
  9. 5 Biotech Stocks That Could Skyrocket From Upcoming Catalysts
  10. Versartis Appoints Tracy Woody as Chief Commercial Officer
  11. Barclays Sees 40% Upside In Versartis Over Next Year
  12. Versartis Announces Data on Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Late-Breaker Presentation at ENDO 2017
  13. Versartis to Present at Cowen & Co. Annual Healthcare Conference and Barclays Global Healthcare Conference
  14. ($$) The Length of a Biotech Patent's Life, Corrected
  15. These Small Biotechs Are Poised to Go Higher
  16. Versartis Reports Fourth Quarter 2016 Financial Results
  17. ($$) Why Biotech Looks Like a Good Bet in 2017
  18. Twitter Is One of Five Stocks Insiders Really Love Right Now
  19. Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer